AMBER KERBOW: Open Payments
NPI 1093235053 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 38 payments from 13 companies in 2025. Trend: 2023 $947 · 2024 $729 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $222 |
| Novo Nordisk Inc | 7 | $131 |
| SANOFI-AVENTIS U.S. LLC | 3 | $65 |
| GlaxoSmithKline, LLC. | 3 | $60 |
| Dexcom, Inc. | 3 | $57 |
| PFIZER INC. | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Astellas Pharma US Inc | 2 | $31 |
| Abbott Laboratories | 1 | $22 |
| SHIELD THERAPEUTICS INC | 1 | $21 |
Products named: JARDIANCE, TZIELD, Dexcom G6 Transmitter, MOUNJARO, PREVNAR 20, Wegovy, Rybelsus, Ozempic.
Industry payments across TX — which companies pay providers there.
